For its third fiscal quarter (ending September 30), Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has reported a 31% increase in E.P.S. from $9.48 a year ago to $12.40 in the current quarter. E.P.S. were $43.24 for the latest four quarters through September 30 versus $37.35 for the same period a year ago — an increase of 16%.
Recent Price Action
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) stock suffered a large decline of -9.2% on 10/31/24. The stock closed at $838.20. Moreover, this decline was accompanied by exceptionally high trading volume at 348% of normal. The stock has been strong relative to the market over the last nine months but has declined -11.0% during the last week.
Current PriceTarget Research Rating
REGN’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be an important Value Builder.
Regeneron Pharmaceuticals has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Regeneron Pharmaceuticals has a slightly positive Power Rating of 69 and a good Appreciation Score of 74, triggering the Positive Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment